Glandular lesions in cervical cytology

Glandular lesions in cervical cytology

Pathology · Obstetrics & Gynaecology

Glandular lesions in cervical cytology represent an important category of epithelial abnormalities that require careful evaluation because they may indicate benign reactive changes, precancerous conditions, or invasive malignancies. Unlike squamous epithelial abnormalities, glandular lesions may originate from the endocervical canal or endometrium, making their identification and interpretation particularly challenging. Atypical glandular cells (AGC) and endocervical adenocarcinoma in situ (AIS) are clinically significant findings because of their association with cervical and, occasionally, extra-cervical malignancies. Human papillomavirus (HPV), particularly high-risk genotypes, plays an important role in the development of cervical glandular neoplasia. Accurate cytological interpretation, appropriate diagnostic evaluation, and timely histopathological confirmation are essential to prevent missed diagnoses and guide clinical management.[1]Classification of glandular abnormalitiesAccording to the Bethesda System for Reporting Cervical Cytology, glandular cell abnormalities include the following categories:AGC: This category includes glandular cells with nuclear abnormalities that exceed reactive changes but do not demonstrate sufficient features for a definitive diagnosis of neoplasiaAGC, not otherwise specified (AGC-NOS): This classification is used when atypical glandular cells are identified without sufficient morphological evidence to suggest a neoplastic processAGC, favor neoplasia: This category indicates more pronounced cytological atypia, raising suspicion of a significant glandular neoplastic lesionAIS: This represents a preinvasive glandular lesion characterized by neoplastic endocervical cells without evidence of stromal invasionAdenocarcinoma: This category indicates malignant glandular cells with cytological features consistent with invasive malignancy[2]Cytological evaluation and diagnostic considerationsGlandular abnormalities should be assessed based on nuclear enlargement, hyperchromasia, irregular nuclear contours, increased nuclear-to-cytoplasmic ratio, and abnormal chromatin distributionArchitectural abnormalities, including crowded cell groups, nuclear overlapping, and pseudostratification, may provide additional evidence of glandular neoplasiaReactive changes, inflammation, metaplasia, and benign endocervical or endometrial cells should be considered during differential diagnosisThe anatomical origin of abnormal glandular cells should be considered because cytological abnormalities may arise from the cervix, endometrium, or other gynecological sitesHPV testing provides additional risk information, particularly when high-risk genotypes associated with glandular neoplasia are detected. However, a negative HPV result does not exclude clinically significant glandular pathology[1]Clinical management and follow-upColposcopic evaluation is recommended for patients with AGC or AIS cytology, irrespective of HPV test results, except when atypical endometrial cells are specifically reportedEndocervical sampling should accompany the initial colposcopic evaluation in nonpregnant patients to assess possible lesions within the endocervical canalEndometrial sampling is recommended in patients aged 35 years or older and in younger patients with clinical indications suggesting increased endometrial neoplasia riskPatients with AGC-NOS without histological evidence of high-grade lesions, AIS, or cancer should undergo cotesting at 1 and 2 years. If both results are negative, repeat cotesting at 3 years is recommendedPatients with AGC favoring neoplasia or AIS cytology require diagnostic excisional evaluation when invasive disease has not been identified during the initial assessment[1]Differential considerations in glandular cytologyPotential sourceRelevant clinical or pathological considerationEndocervical polypsBenign glandular proliferation may produce cytological atypia.Tubal metaplasiaBenign metaplastic changes may mimic glandular abnormalities.Endometrial hyperplasiaMay contribute to abnormal glandular cell findings, particularly in patients with abnormal uterine bleeding.Endometrial carcinomaShould be considered when atypical endometrial cells are identified.Cervical adenocarcinomaRequires histopathological evaluation to establish invasion and tumor classification.ConclusionGlandular lesions in cervical cytology require a systematic diagnostic approach because their clinical significance ranges from benign cellular alterations to invasive malignancy. Accurate classification using Bethesda terminology, appropriate HPV assessment, colposcopy, and targeted endocervical or endometrial sampling are essential components of evaluation. Importantly, AGC and AIS findings should not be dismissed solely because HPV testing is negative. Timely histopathological assessment and guideline-directed follow-up remain central to identifying significant glandular disease and optimizing patient outcomes.Reference(s):1. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525. https://pmc.ncbi.nlm.nih.gov/articles/PMC7147428/2. Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology: A Historical Perspective. Acta Cytol. 2017;61(4-5):359-372. doi:10.1159/000477556. https://pubmed.ncbi.nlm.nih.gov/28693017/